The Regeneron Pharmaceuticals, Inc. (REGN) revenue growth is 8.3%, which is lower than the industry median of 12.6% and the 5-year historical average of 16.5%.
The Regeneron Pharmaceuticals, Inc. (REGN) operating income growth is (0.6%), compared to the industry median of 10.6% and the 5-year historical average of 26.5%.
The Regeneron Pharmaceuticals, Inc. (REGN) EPS growth is 10.3%, compared to the industry median of (19.3%) and the 5-year historical average of 27.2%.
The Regeneron Pharmaceuticals, Inc. (REGN) Free Cash Flow growth is (5.7%), compared to the industry median of (3.4%) and the 5-year historical average of 44.5%.